Almotriptan

Almotriptan
Clinical data
Trade names	Axert
AHFS/Drugs.com	Monograph
MedlinePlus	a603028
License data	US DailyMed: Almotriptan;
Routes of; administration	By mouth
ATC code	N02CC05 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	70%
Protein binding	35%
Metabolism	Liver
Elimination half-life	3–4 hours
Identifiers
	IUPAC name N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine;
CAS Number	154323-57-6 ;
PubChem CID	123606;
IUPHAR/BPS	7110;
DrugBank	DB00918 ;
ChemSpider	110198 ;
UNII	1O4XL5SN61;
KEGG	D02824 ; as salt: D02825 ;
ChEBI	CHEBI:520985 ;
ChEMBL	ChEMBL1505 ;
CompTox Dashboard (EPA)	DTXSID5044289 ;
Chemical and physical data
Formula	C17H25N3O2S
Molar mass	335.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCc2c[nH]c3ccc(CS(=O)(=O)N1CCCC1)cc23;
	InChI InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3 ; Key:WKEMJKQOLOHJLZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Almotriptan (trade name Axert and others) is a triptan medication discovered and developed by Almirall for the treatment of heavy migraine headache.

It was patented in 1992 and approved for medical use in 2000.